Over the past two decades, risk assessment for inherited cancers has been driven by syndrome specific models for the identification of high risk individuals who should undergo genetic testing. Genetic testing results allow the clinician to ensure strategies for surveillance and/or intervention to prevent cancer in susceptible individuals. This motivated our previous work in development of the PREMM models, the most recent of which predicts risk of mutation in 5 genes that cause Lynch syndrome. The PREMM models have been incorporated into national guidelines for the identification of Lynch syndrome. Parallel syndrome specific models have been developed for hereditary breast and ovarian cancer (HBOC) based on the prediction of two genes (BRCA1,2). While these models are well accepted in clinical practice, many individuals with hereditary cancer syndromes remain unidentified as current models predict risk of a limited number of gene mutations. Evidence from the use of multigene panel tests has provided an opportunity for the evolution of hereditary risk assessment models that can lead to increased identification of high risk individuals. These tests have found that an additional 15+ genes are implicated in both Lynch syndrome and HBOC, and that there is overlap in genetic profiles across syndromes i.e. BRCA1/2 detected in Lynch patients and mismatch repair gene mutations detected in HBOC patients. To address these unmet needs and as an extension of our prior work, we propose to develop a multigene model that will predict risk of mutation in 20+ genes including the genes in current models for HBOC and Lynch syndromes as well as an additional 15+ cancer susceptibility genes. We will develop the multigene model in a study of more than 260,000 individuals both affected and unaffected with cancer, compare its performance to current syndrome specific models, and perform validation in separate populations. To this end, we propose the following specific aims: 1. To develop a genetic risk assessment tool that will identify individuals who should undergo multigene panel testing for germline mutations associated with inherited cancer susceptibility genes, 2. To compare the performance of the multigene risk assessment model with syndrome specific models, including PREMM1,2,6, MMRpro, and BRCAPRO in a cohort of 2000 ethnically and racially diverse patients, and 3. To externally validate the multigene risk-assessment model in (A) a clinic- based population of patients without a personal history of cancer referred for hereditary cancer risk assessment due to a family history of cancer and (B) unselected clinic-based populations of patients with colorectal, breast, and pancreatic cancer. This work will lead to streamlined and comprehensive genetic risk assessment of personal and family cancer histories and the first prediction model that can be used by clinicians to determine who should undergo multigene panel genetic testing. Systematic application of this model in clinical practice will lead to increased identification of individuals who carry mutations in cancer susceptibility genes while reducing the number of low-risk individuals undergoing genetic testing.

Public Health Relevance

The results of this effort will lead to the development and validation of a comprehensive risk assessment model that will predict the likelihood of carrying a germline cancer susceptibility mutation on multigene panel testing. It builds upon the investigative team's previous work on colorectal and breast-ovarian cancer syndrome-specific models which are limited to the prediction of mutation in 2-5 genes, expanding it in scope to include data on an additional 15+ cancer susceptibility genes generated from multigene panel testing. The result of this work will be a comprehensive, streamlined model that will predict mutation in a broad range of genes, increasing the identification of those at risk for a number of inherited cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA132829-10
Application #
9625073
Study Section
Cancer, Heart, and Sleep Epidemiology B Study Section (CHSB)
Program Officer
Shelburne, Nonniekaye F
Project Start
2008-09-30
Project End
2023-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
10
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Luba, Daniel G; DiSario, James A; Rock, Colleen et al. (2018) Community Practice Implementation of a Self-administered Version of PREMM1,2,6 to Assess Risk for Lynch Syndrome. Clin Gastroenterol Hepatol 16:49-58
Kastrinos, Fay; Uno, Hajime; Ukaegbu, Chinedu et al. (2017) Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol 35:2165-2172
Yurgelun, Matthew B; Kulke, Matthew H; Fuchs, Charles S et al. (2017) Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol 35:1086-1095
Kastrinos, Fay; Ojha, Rohit P; Leenen, Celine et al. (2016) Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. J Natl Cancer Inst 108:
Inra, Jennifer A; Steyerberg, Ewout W; Grover, Shilpa et al. (2015) Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing. Genet Med 17:815-21
Yurgelun, Matthew B; Allen, Brian; Kaldate, Rajesh R et al. (2015) Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology 149:604-13.e20
Kastrinos, Fay; Steyerberg, Ewout W (2015) Family matters in lynch syndrome. J Natl Cancer Inst 107:
Everett, Jessica N; Raymond, Victoria M; Dandapani, Monica et al. (2014) Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. JAMA Dermatol 150:1315-21

Showing the most recent 10 out of 14 publications